A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2921-2926

  Kullar, Ravina ^a,h   Casapao, Anthony M ^a   Davis, Susan L ^a,b   Levine, Donald P ^a,c   Zhao, Jing J ^d   Crank, Christopher W ^e   Segreti, John ^e   Sakoulas, George ^f   Cosgrove, Sara E ^g   Rybak, Michael J ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Henry Ford Health System Division of Infectious Diseases   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Infections; MRSA; Patient outcomes

Indexed keywords

COTRIMOXAZOLE; CREATINE KINASE; DAPTOMYCIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SALVAGE THERAPY; STAPHYLOCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

INFECTIONS; MRSA; PATIENT OUTCOMES;

ADULT; ANTI-BACTERIAL AGENTS; BLOOD; DAPTOMYCIN; ENDOCARDITIS; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 84887538700     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt294     Document Type: Article

References (35)

1. Benito N, Miro JM, de Lazzari E et al. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med 2009; 150: 586-94.
2. Fernandez-Hidalgo N, Almirante B, Tornos P et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis 2008; 47: 1287-97.
3. Grundmann H, Aires-de-Sousa M, Boyce J et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368: 874-85.
4. Fridkin SK, Lawton R, Edwards JR et al. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8: 702-7.
5. Fowler VG Jr, Miro JM, Hoen B et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293: 3012-21.
6. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
7. Kullar R, Davis SL, Levine DP et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52: 975-81.
8. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
9. Khatib R, Johnson LB, Fakih MG et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38: 7-14.
10. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-603.
11. Mortin LI, Li T, Van Praagh AD et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007; 51: 1787-94.
12. Arbeit RD, Maki D, Tally FP et al. The safetyand efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
13. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
14. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-9.
15. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60: 334-40.
16. Rose WE, Leonard SN, Sakoulas G et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 831-6.
17. Chambers HF, Basuino L, Diep BA et al. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother 2009; 53: 1463-7.
18. Hall AD, Steed ME, Arias CA et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56: 3174-80.
19. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 3061-7.
20. Katz DE, Lindfield KC, Steenbergen JN et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int J Clin Pract 2008; 62: 1455-64.
21. Mohr JF, Friedrich LV, Yankelev S et al. Daptomycin for the treatment of enterococcal bacteraemia: results fromthe Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009; 33: 543-8.
22. Figueroa DA, Mangini E, Amodio-Groton M et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49: 177-80.
23. Moise PA, Hershberger E, Amodio-Groton MI et al. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43: 1211-9.
24. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-92.
25. Kullar R, Davis SL, Levine DP et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31: 527-36.
26. Durante-Mangoni E, Casillo R, Bernardo M et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 2012; 54: 347-54.
27. Product Information: Cubicinw, Daptomycin For Injection. Lexington, MA: Cubist Pharmaceuticals, Inc., 2003.
28. Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-8.
29. Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treatedwithhigh-dosedaptomycin.Heart Lung2007;36:456-61.
30. Cunha BA, Krol V, Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008; 37: 72-5.
31. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120 Suppl 1: S28-33.
32. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49: 2735-45.
33. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother 1989; 33: 1522-5.
34. Tedesco KL, Rybak MJ. Daptomycin. Pharmacother 2004; 24: 41-57.
35. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.